A single-nucleotide polymorphism (rs8176070) of lncRNA PART1 may reflect the risk for knee osteoarthritis

lncRNA PART1 mitigates MPP+-induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis

OBJECTIVE

Parkinson's disease (PD) is a neurodegenerative disease caused by the loss of dopaminergic neurons. Here, we aimed to explore the function of LncRNA PART1 in PD and its underlying mechanisms.

METHODS

An in vivo MPTP-induced mouse model of PD was generated and the SH-SY5Y cells were treated with MPP⁺ to induce neuronal damage in vitro. The expressions of LncRNA PART1 and microRNA-106b-5p were assessed by RT-qPCR. The level of caspase 3 protein was detected by western blot. CCK8 assay and Annexin V/PI staining were used for detecting cell viability and survival rate, respectively. The interactions between microRNA-106b-5p and LncRNA PART1 or MCL1 were determined by RNA pull-down assay, RIP assay and DLR assay. The levels of inflammatory cytokines were assessed by ELISA, and the levels of LDH, ROS or SOD were verified using the appropriate assay kits.

RESULTS

The expression of LncRNA PART1 was decreased in PD model in vivo and in vitro (all P<0.05). In SH-SY5Y cells treated with MPP⁺, the overexpression of LncRNA PART1 increased cell viability and reduced cell apoptosis, the secretion of inflammatory cytokines and oxidative stress reaction (all P<0.05). Furthermore, LncRNA PART1 sponged microRNA-106b-5p which directly targeted MCL1 and thus regulated the expression of MCL1. LncRNA PART1 attenuated the injury of SH-SY5Y cells induced by MPP⁺ via targeting microRNA-106b-5p and enhancing MCL1 expression.

CONCLUSION

LncRNA PART1 could alleviate the damage effects of MPP⁺ on SH-SY5Y cells by regulating microRNA-106b-5p/MCL1 axis, suggesting the potential therapeutic value of LncRNA PART1 as a target in PD.

Role of Long Non-Coding RNA Polymorphisms in Cancer Chemotherapeutic Response

Genetic polymorphisms are defined as the presence of two or more different alleles in the same locus, with a frequency higher than 1% in the population. Since the discovery of long non-coding RNAs (lncRNAs), which refer to a non-coding RNA with a length of more than 200 nucleotides, their biological roles have been increasingly revealed in recent years. They regulate many cellular processes, from pluripotency to cancer. Interestingly, abnormal expression or dysfunction of lncRNAs is closely related to the occurrence of human diseases, including cancer and degenerative neurological diseases. Particularly, their polymorphisms have been found to be associated with altered drug response and/or drug toxicity in cancer treatment. However, molecular mechanisms are not yet fully elucidated, which are expected to be discovered by detailed studies of RNA–protein, RNA–DNA, and RNA–lipid interactions. In conclusion, lncRNAs polymorphisms may become biomarkers for predicting the response to chemotherapy in cancer patients. Here we review and discuss how gene polymorphisms of lncRNAs affect cancer chemotherapeutic response. This knowledge may pave the way to personalized oncology treatments.